Audit: QRS - Flossing for Health & Longevity

Audit conducted on 07/10/2026 06:34 using AI4L / Opus 5.5

Iterations

Summary

Items	Count
Total	94
Passed	88
Failed	0
N/A	6
Pass Rate	100.00%

• Total = Passed + Failed + N/A
• Pass Rate = Passed / (Passed + Failed) × 100
• N/A items are excluded from the pass rate calculation

---

1. General Rules

#	Description	Result	Comments
1.1	Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER.	🟢
1.2	Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing.	🟢	“(theoretical)” qualifiers carried through in interactions and the extraction-site contraindication
1.3	The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”).	🟢
1.4	The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc.	🟢
1.5	PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact.	🟢
1.6	The QRS does not introduce new attributions.	🟢

2. Focus, Tone & Audience

#	Description	Result	Comments
2.1	The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing.	🟢
2.2	The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging	🟢
2.3	The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor	🟢
2.4	The QRS avoids language that implies medical or clinical advice	🟢
2.5	The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising”	🟢
2.6	The QRS never addresses “the reader” directly — it presents evidence, not guidance	🟢
2.7	The QRS is written in plain language, avoiding unnecessary medical jargon	🟢
2.8	Information is presented in a concise and very compact manner	🟢
2.9	It DOES NOT address the reader directly	🟢
2.10	The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review.	🟢
2.11	The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort.	🟢
2.12	The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort.	🟢
2.13	Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience.	🟢
2.14	The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim.	🟢
2.15	The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “oral” / “administered orally” not “taken by mouth” / “given by mouth”; “injection” not “shot”; “adverse event” not “bad reaction”). This holds on EVERY surface, including the QRS lede — the stricter plain-language bar (see 2.7) does not license lay phrasing for route of administration. Direct quotes from sources are exempt.	🟢

3. Template Integrity

#	Description	Result	Comments
3.1	The following labels and headings on the QRS are fixed and not modified: • Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment” • Gate headings: “Contraindications”, “Key Interactions” • Tier labels: “High”, “Medium”, “Low”, “Speculative” • Table column headers in Monitoring: “Marker”, “Target”, “Why”	🟢
3.2	All “…” from the [qrs_template] are present in the the QRS.	🟢	Diff against template: all data-qrs-var spans present; marker/qualitative spans numbered 1–6 / 1–5
3.3	Spans that are not addressed in a checklist item are left unchanged	🟢	Only checklist-addressed spans changed; display:none added only on empty High tiers and unused time_3 cell

4. Formatting

#	Description	Result	Comments
4.1	When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied”	🟢
4.2	Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label.	🟢
4.3	Labels are not paraphrased, abbreviated, or invented.	🟢
4.4	The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels.	🟢	No emoji in QRS
4.5	The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page.	🟢

5. Metadata

#	Description	Result	Comments
5.1	The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content.	🟢	Metadata comment at line 2, directly after doctype
5.2	Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML.	🟢
5.3	The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet.	🟢
5.4	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢
5.5	The filename of the source ER is stated as “er_filename: [er_filename]”	🟢
5.6	Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]”	🟢
5.7	Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430)	🟢
5.8	The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]”	🟢
5.9	The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT)	🟢
5.10	The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]”	🟢
5.11	The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4)	🟢
5.12	The filename of the document is stated as “qrs_filename: [filename of this document]”	🟢
5.13	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢

6. Page Title & Header

#	Description	Result	Comments
6.1	[page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &)	🟢	“Flossing for Health & Longevity - Quick Reference Sheet”
6.2	[header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &)	🟢
6.3	[header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY]	🟢	2026-1007-0606 → 10/07/2026
6.4	[header_subline_model] is set to [qrs_creator_ai_fullname]	🟢
6.5	No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker.	🟢

7. At-A-Glance Section

#	Description	Result	Comments
7.1	[at_a_glance] opens by saying what the intervention is — its kind (e.g., dietary supplement, prescription medication, peptide, plant, procedure, practice) — and what it is used for, in plain language, before any verdict on the evidence	🟢	Opens with “a daily oral-care practice of passing a thin strand between teeth to clear the bacterial film a toothbrush misses”
7.2	[at_a_glance] is dense, execution-oriented summary of the ER Conclusion section	🟢
7.3	[at_a_glance] is no longer than 70 words	🟢	70 words (script count)
7.4	Every fact in [at_a_glance] is supported by a distinct passage in the ER.	🟢
7.5	It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead	🟢
7.6	It DOES NOT cite specific trials (names, years, sample sizes, p-values)	🟢
7.7	It DOES NOT cite effect sizes, relative risks, or statistical results	🟢

8. Contraindications

#	Description	Result	Comments
8.1	The section is derived from the ER Key Interactions & Contraindications section	🟢
8.2	[stop_items] represent the Contraindications from the ER	🟢	4 items match ER “Populations who should avoid Flossing”
8.3	Individual [stop_items] are formatted as <li></li>	🟢
8.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢
8.5	Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢
8.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	ER contraindications use no ranking notation inside parens
8.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision.	🟢
8.8	If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g.	N/A	Section is not empty (4 items)

9. Key Interactions

#	Description	Result	Comments
9.1	The section is derived from the ER Key Interactions & Contraindications section	🟢
9.2	[caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications	🟢	All 10 ER interaction bullets represented; none duplicates a contraindication
9.3	Individual [caution_items] are formatted as <li></li>	🟢
9.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢
9.5	Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢
9.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	ER interactions use no ranking notation inside parens
9.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used.	🟢
9.8	If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g.	N/A	Section is not empty (10 items)

10. Protocol

#	Description	Result	Comments
10.1	The section is derived from the ER Protocol section	🟢
10.2	The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section	🟢	Standard frequency, Technique, Sequence (ER bold labels)
10.3	If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	ER Therapeutic Protocol provides more than three actionable aspects; all three sets used
10.4	All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section.	🟢

11. Time to Effect

#	Description	Result	Comments
11.1	The three sets of [time] items cover the three most important time-to-effect aspects from the ER	🟢
11.2	The sets are picked and ordered by the magnitude of the related benefit	🟢
11.3	If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	🟢	ER gives two time-to-effect aspects; time_3 cell empty and hidden
11.4	All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER.	🟢
11.5	If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel	N/A	ER provides time-to-effect information (Practical Considerations)

12. Benefits

#	Description	Result	Comments
12.1	The section is derived from the ER Expected Benefits section	🟢
12.2	Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative]	🟢
12.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢
12.4	Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢
12.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	🟢	High tier hidden with display: none

13. Risks

#	Description	Result	Comments
13.1	The section is derived from the ER Potential Risks & Side Effects section	🟢
13.2	Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative]	🟢
13.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢
13.4	Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢
13.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	🟢	High tier hidden with display: none

14. Monitoring

#	Description	Result	Comments
14.1	The section is derived from the ER Monitoring section	🟢
14.2	All measurable/quantifiable biomarkers from the Monitoring section are listed	🟢	All 5 ER table biomarkers plus INR from the Monitoring narrative
14.3	[monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty.	🟢

15. Qualitative Assessment

#	Description	Result	Comments
15.1	The section is derived from the ER Monitoring section	🟢
15.2	All subjective/qualitative biomarkers from the Monitoring section are listed	🟢	All 5 ER qualitative markers listed

Issues 07/10/2026 06:34

Pass rate 100.00%. No issues found.

Issues 07/10/2026 06:30

1. 4.3 — Monitoring marker label paraphrased: marker_3_name (line 625) reads “Clinical attachment level between teeth” instead of the ER biomarker label “Interproximal clinical attachment level” (ER Monitoring table, line 378).

Fixes 07/10/2026 06:30

1. 4.3 — Monitoring marker label restored: Changed marker_3_name from “Clinical attachment level between teeth” to the ER biomarker label “Interproximal clinical attachment level”.

Issues 07/10/2026 06:29

1. 1.3 — Single-trial finding stated generally: Protocol action_3_sub (line 472) says “Removed more plaque between teeth and retained more fluoride” without the ER’s qualifier that this was the finding of one randomized crossover trial, strengthening the claim.
2. 2.7 — Jargon in marker name: Monitoring marker_3_name (line 625) uses “Interproximal clinical attachment level”; “interproximal” is unnecessary jargon where the sheet otherwise says “between teeth”.

Fixes 07/10/2026 06:29

1. 1.3 — Single-trial qualifier restored: Changed action_3_sub from “Removed more plaque between teeth…” to “In one trial, removed more plaque between teeth…”, matching the ER’s single-crossover-trial framing.
2. 2.7 — Plain-language marker name: Renamed marker_3_name from “Interproximal clinical attachment level” to “Clinical attachment level between teeth”.

Issues 07/10/2026 06:25

1. 4.3 — Monitoring marker label paraphrased: marker_3_name (line 625) reads “Clinical attachment level between teeth” instead of the ER Monitoring table label “Interproximal clinical attachment level”.

Fixes 07/10/2026 06:25

1. 4.3 — Monitoring marker label restored: Changed marker_3_name from “Clinical attachment level between teeth” to the ER label “Interproximal clinical attachment level”.

Issues 07/10/2026 06:22

1. 1.1 — Unsupported INR target claim: Monitoring marker_6_target (line 661) states “No established target” for INR, which the ER never says; the ER only notes that people on anticoagulants add their usual clotting tests and that a high INR changes how flossing is done.
2. 2.15 — Colloquial “cheap” in lede: The At-a-glance text (line 433) calls flossing “cheap” rather than using the formal “inexpensive” found in the ER.
3. 4.3 — Risk label altered: The speculative risk (line 584) inserts “Teflon-type” into the ER label “Exposure to Fluorinated Chemicals From PTFE Floss”.

Fixes 07/10/2026 06:22

1. 1.1 — Unsupported INR target claim: Changed marker_6_target from “No established target; a high INR changes how flossing is done” to “Per usual clotting tests; a high INR changes how flossing is done”, matching the ER Monitoring text.
2. 2.15 — Colloquial “cheap” in lede: Replaced “cheap” with “inexpensive” in the At-a-glance text (word count unchanged at 70).
3. 4.3 — Risk label altered: Removed the inserted “Teflon-type” so the speculative risk reads “Exposure to fluorinated chemicals from PTFE floss”, matching the ER label.

Issues 07/10/2026 06:20

1. 4.1 — Invented empty-state phrasing for INR: The marker_6_target cell (line 661) reads “Not specified; a high INR changes how flossing is done”, but the ER’s own phrasing for a marker without a target is “No established target” (ER Monitoring table).

Fixes 07/10/2026 06:20

1. 4.1 — INR target empty-state phrasing: Changed marker_6_target from “Not specified; a high INR changes how flossing is done” to “No established target; a high INR changes how flossing is done”, matching the ER’s empty-state phrasing.

Issues 07/10/2026 06:16

1. 13.4 — Parenthetical retained in risk: The Risks Speculative item (QRS line 584) reads “Exposure to fluorinated chemicals from Teflon-type (PTFE) floss”, keeping the parenthetical “(PTFE)” that must be stripped.

Fixes 07/10/2026 06:16

1. 13.4 — Parenthetical removed from risk: Changed the Risks Speculative item from “Exposure to fluorinated chemicals from Teflon-type (PTFE) floss” to “Exposure to fluorinated chemicals from Teflon-type PTFE floss”, stripping the parentheses.

Issues 07/10/2026 06:14

1. 2.7 — Unexplained jargon and acronyms: “PTFE floss” (risks_speculative, line 584), “ADA” (action_3_sub, line 472), “interdental cleaner” (action_1_sub, line 450) and “Interproximal” (marker_3_name, line 625) are used without plain-language explanation.
2. 14.2 — Clotting test marker missing: The ER Monitoring section names clotting tests (INR) for people on anticoagulants as a measurable baseline marker (ER line 370), but the QRS Monitoring table omits it.

Fixes 07/10/2026 06:14

1. 2.7 — Unexplained jargon and acronyms: Replaced “PTFE floss” with “Teflon-type (PTFE) floss”, “ADA” with “American Dental Association”, “interdental cleaner” with “between-teeth cleaner”, and “Interproximal clinical attachment level” with “Clinical attachment level between teeth”.
2. 14.2 — Clotting test marker missing: Added a Monitoring row for the INR clotting test (only on anticoagulants), with target and rationale taken from the ER Monitoring and Risk-Modifying Factors text.

Issues 07/10/2026 06:11

1. 4.2 / 4.3 — Protocol label abbreviated: Line 444 shows action_1_label “Standard frequency” instead of the ER bold label “Standard frequency (conventional dentistry)” (ER line 320).
2. 11.1 / 11.3 / 4.3 — Relapse used as time-to-effect: Lines 503-513 fill the third time set with “Relapse after stopping / 10–21 days” from ER Discontinuation & Cycling, which is loss of effect rather than time to effect, under an invented label; the ER names only two time-to-effect aspects, so the third set should be empty and invisible.
3. 12.4 — Benefit parenthetical retained: Line 525 keeps the parenthetical “(gingivitis)” in “Less gum inflammation (gingivitis)” although parenthetical content in Benefits must be stripped.

Fixes 07/10/2026 06:11

1. 4.2 / 4.3 — Protocol label restored verbatim: Changed action_1_label from “Standard frequency” to the ER bold label “Standard frequency (conventional dentistry)”.
2. 11.1 / 11.3 / 4.3 — Relapse time set removed: Emptied time_3_label, time_3_value and time_3_sub (“Relapse after stopping / 10–21 days”) and hid that cell with display: none, since the ER names only two time-to-effect aspects.
3. 12.4 — Benefit parenthetical stripped: Changed “Less gum inflammation (gingivitis)” to “Less gum inflammation” in benefits_medium.

Issues 07/10/2026 06:08

1. 2.7 — Specialist term in Monitoring: marker_4_why (line 642) reads “Fewer new interproximal lesions”, using the specialist term “interproximal” where plain “between teeth” wording is available.
2. 7.3 — At-a-glance exceeds 70 words: The [at_a_glance] text (line 433) is 71 words, one over the 70-word limit.

Fixes 07/10/2026 06:08

1. 2.7 — Specialist term in Monitoring: Changed marker_4_why from “Fewer new interproximal lesions” to “Fewer new decay lesions between teeth”.
2. 7.3 — At-a-glance exceeds 70 words: Changed “between the teeth” to “between teeth” in the first sentence, bringing [at_a_glance] to 70 words.